Blood Cancer UK

Blood Cancer UK has delivered a strong and impactful performance in 2025/26, standing out in a challenging climate for the voluntary sector. While many charities have faced rising costs and income pressures, the organisation has maintained high levels of fundraising, with income on track to match the previous year’s £19.3 million. This financial resilience has enabled continued and expanded investment in life-saving research.

We’ve launched our new research strategy, committing up to £70 million in new awards between now and 2030. We’ve launched our Transformational Research Awards and other targeted funding such as the £7.4 million Matthew Wilson Multiple Myeloma Fund, accelerating progress in one of the hardest to treat blood cancers. Investment in early-career researchers further strengthens the future pipeline of scientific talent.

We have also demonstrated tangible policy impact. Successful campaigning contributed to key commitments in England’s National Cancer Plan, including guaranteed access to named Clinical Nurse Specialists and expanded diagnostic support. These changes that will directly improve patient experience and outcomes.

Our culture remains strong, with 95% of staff recommending the organisation as a great place to work.

Together we’ve achieved a huge amount this year, and over the past 65 years. There’s still much more to be done before blood cancer is beaten, but we know that the strength of our fundraising, research and advocacy work in 2026 puts us in a great place to accelerate the day when no one dies from blood cancer.